Nouryon

ADW Tablet formulation

Description

Dissolvine@ M-X helps in chelation, Anti encrustation & ARD benefits.

Berol® LFG 61 is a blend of nonionic surfactant effective in de greasing with low foaming.

Alcosperse@ 602N Dry is excellent in soil suspension & ARD benefits. It also helps in corrosion

resistance.

<u>Finnfix M90S</u> helps in binding tablet & sustainable release during application.

Formula

Trade Name	Chemical Name	% w/w	Supplier
Soda Ash	Sodium carbonate	45.5	Local
Sodium Percarbonate	Sodium Percarbonate	21	Local
TAED	Tri acetyl ethylenediamine	4	Local
Dissolvine [@] M-X	Methylglycine N,N-diacetic acid, trisodium salt	9	Nouryon
Berol [®] LFG 61	Blend of alcohol ethoxylate and alkyl glucoside	11.5	Nouryon
Sodium metasilicate	Sodium metasilicate	0.95	Local
Alcosperse@ 602N Dry	Tetrasodium glutamate diacetate	2	Nouryon
Finnfix@ M90S	Sodium Carboxymethyl cellulose	2	Nouryon
Protease	proteinase	1.5	Local
Amylase	alpha amylase	1.5	Local
Fragrance	Fragrance	0.5	Local
Preservative	Phenoxyethanol	0.5	Local
	Total:	100.00%	

Procedure:

- 1. Add Soda Ash, Sodium Percarbonate & TAED in powder mixer/ Sigma mixer / Ribbon blender
- Add Dissolvine M-X, Berol LFG 61 & mix well till all powder becomes homogeneous & no lumps are observed.
- 3. Add Sodium metasilicate, Alcosperse 602N Dry and mix well for 15 min
- 4. Add Finnfix M90S and mix well followed by addition of enzymes. Mix well till all powder becomes homogeneous.
- 5. Add preservative, dye, fragrance and other additives and mix until homogeneous

Properties:

Appearance:	Clear liquid
pH:	10.0 – 11.0

The information given and the recommendations made herein are based on our research and are believed to be accurate but no guarantee of their accuracy is made. In every case we urge and recommend that purchasers before using any product in full scale production make their own tests to determine to their own satisfaction whether the product is of acceptable quality and is suitable for their particular purposes under their own operating conditions. The results of toxicity testing of the polymers used in the formulations are found in the respective technical literature, the safety of the formulation has not been established by testing. The suitability of the final formulation should be confirmed in all respects by appropriate evaluation. No representative of ours has any authority to waive or change the foregoing provisions but, subject to such provisions, our engineers are available to assist purchasers in adapting our products to their needs and to the circumstances prevailing in their business. Nothing contained herein shall be construed to imply the nonexistence of any relevant patents or to constitute a permission, inducement or recommendation to practice any invention covered by any patent, without the authority from the owner of this patent. We also expect purchasers to use our products in accordance with the guiding principles of the Chemical Manufacturers Association's Responsible Care® program.